1. Paton JC. The contribution of pneumolysin to the pathogenicity of Streptococcus pneumoniae. Trends Microbiol. 1996. 4:103–106.
Article
2. Paton JC, Lock RA, Lee CJ, et al. Purification and immunogenicity of genetically obtained pneumolysin toxoids and their conjugation to Streptococcus pneumoniae type 19F polysaccharide. Infect Immun. 1991. 59:2297–2304.
Article
3. Gray BM, Converse GM 3rd, Dillon HC Jr. Epidemiologic studies of Streptococcus pneumoniae in infants: acquisition, carriage, and infection during the first 24 months of life. J Infect Dis. 1980. 142:923–933.
Article
4. Park IH, Pritchard DG, Cartee R, Brandao A, Brandileone MC, Nahm MH. Discovery of a new capsular serotype (6C) within serogroup 6 of Streptococcus pneumoniae. J Clin Microbiol. 2007. 45:1225–1233.
Article
5. Bogaert D, Hermans PW, Adrian PV, Rumke HC, de Groot R. Pneumococcal vaccines: an update on current strategies. Vaccine. 2004. 22:2209–2220.
Article
6. Isaacman DJ, McIntosh ED, Reinert RR. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int J Infect Dis. 2010. 14:e197–e209.
Article
7. Oosterhuis-Kafeja F, Beutels P, Van Damme P. Immunogenicity, efficacy, safety and effectiveness of pneumococcal conjugate vaccines (1998-2006). Vaccine. 2007. 25:2194–2212.
Article
8. Poolman JT. Pneumococcal vaccine development. Expert Rev Vaccines. 2004. 3:597–604.
Article
9. Jambo KC, Sepako E, Heyderman RS, Gordon SB. Potential role for mucosally active vaccines against pneumococcal pneumonia. Trends Microbiol. 2010. 18:81–89.
Article
10. Kayhty H, Auranen K, Nohynek H, Dagan R, Makela H. Nasopharyngeal colonization: a target for pneumococcal vaccination. Expert Rev Vaccines. 2006. 5:651–667.
Article
11. Brandtzaeg P. Molecular and cellular aspects of the secretory immunoglobulin system. APMIS. 1995. 103:1–19.
Article
12. Aaberge IS, Groeng EC, Haugen IL, Dalseg R, Lovik M, Haneberg B. Induction of systemic and mucosal antibodies to pneumococcal antigens by mucosal immunization. J Cell Biochem Suppl. 1995. 19A:242.
13. Hvalbye BK, Aaberge IS, Lovik M, Haneberg B. Intranasal immunization with heat-inactivated Streptococcus pneumoniae protects mice against systemic pneumococcal infection. Infect Immun. 1999. 67:4320–4325.
Article
14. McEllistrem MC, Adams J, Mason EO, Wald ER. Epidemiology of acute otitis media caused by Streptococcus pneumoniae before and after licensure of the 7-valent pneumococcal protein conjugate vaccine. J Infect Dis. 2003. 188:1679–1684.
Article
15. Oliveira ML, Areas AP, Ho PL. Intranasal vaccines for protection against respiratory and systemic bacterial infections. Expert Rev Vaccines. 2007. 6:419–429.
Article
16. Kim EH, Choi SY, Kwon MK, et al. Streptococcus pneumoniae pep27 mutant as a live vaccine for serotype-independent protection in mice. Vaccine. 2012. 30:2008–2019.
Article
17. Avery OT, Macleod CM, McCarty M. Studies on the chemical nature of the substance inducing transformation of pneumococcal types: induction of transformation by a desoxyribonucleic acid fraction isolated from pneumococcus type III. J Exp Med. 1944. 79:137–158.
18. Ottolenghi E, Hotchkiss RD. Release of genetic transforming agent from pneumococcal cultures during growth and disintegration. J Exp Med. 1962. 116:491–519.
Article
19. Briles DE, Nahm M, Schroer K, et al. Antiphosphocholine antibodies found in normal mouse serum are protective against intravenous infection with type 3 Streptococcus pneumoniae. J Exp Med. 1981. 153:694–705.
Article
20. Aaberge IS, Eng J, Lermark G, Lovik M. Virulence of Streptococcus pneumoniae in mice: a standardized method for preparation and frozen storage of the experimental bacterial inoculum. Microb Pathog. 1995. 18:141–152.
Article
21. Briles DE, Crain MJ, Gray BM, Forman C, Yother J. Strong association between capsular type and virulence for mice among human isolates of Streptococcus pneumoniae. Infect Immun. 1992. 60:111–116.
Article
22. Andersson B, Dahmen J, Frejd T, et al. Identification of an active disaccharide unit of a glycoconjugate receptor for pneumococci attaching to human pharyngeal epithelial cells. J Exp Med. 1983. 158:559–570.
Article
23. Weng L, Biswas I, Morrison DA. A self-deleting Cre-lox-ermAM cassette, Cheshire, for marker-less gene deletion in Streptococcus pneumoniae. J Microbiol Methods. 2009. 79:353–357.
Article
24. Havarstein LS, Coomaraswamy G, Morrison DA. An unmodified heptadecapeptide pheromone induces competence for genetic transformation in Streptococcus pneumoniae. Proc Natl Acad Sci U S A. 1995. 92:11140–11144.
Article
25. Bricker AL, Camilli A. Transformation of a type 4 encapsulated strain of Streptococcus pneumoniae. FEMS Microbiol Lett. 1999. 172:131–135.
Article
26. Kwon HY, Kim SW, Choi MH, et al. Effect of heat shock and mutations in ClpL and ClpP on virulence gene expression in Streptococcus pneumoniae. Infect Immun. 2003. 71:3757–3765.
Article
27. Roche AM, Weiser JN. Identification of the targets of cross-reative antibodies induced by Streptococcus pneumoniae colonization. Infect Immun. 2010. 78:2231–2239.
Article
28. Roche AM, King SJ, Weiser JN. Live attenuated Streptococcus pneumoniae strains induce serotype-independent mucosal and systemic protection in mice. Infect Immun. 2007. 75:2469–2475.
Article
29. Pneumococcal vaccines. WHO position paper. Wkly Epidemiol Rec. 1999. 74:177–183.
30. Tyrrell GJ, Lovgren M, Chui N, et al. Serotypes and antimicrobial susceptibilities of invasive Streptococcus pneumoniae pre- and post-seven valent pneumococcal conjugate vaccine introduction in Alberta, Canada, 2000-2006. Vaccine. 2009. 27:3553–3560.
Article
31. Gladstone RA, Jefferies JM, Faust SN, Clarke SC. Continued control of pneumococcal disease in the UK: the impact of vaccination. J Med Microbiol. 2011. 60(Pt 1):1–8.
Article
32. Malley R, Lipsitch M, Stack A, et al. Intranasal immunization with killed unencapsulated whole cells prevents colonization and invasive disease by capsulated pneumococci. Infect Immun. 2001. 69:4870–4873.
Article
33. Mutsch M, Zhou W, Rhodes P, et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med. 2004. 350:896–903.
Article
34. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983. 65:55–63.
Article